TESARO Inc (TSRO) is Reiterated by Mizuho to Buy, Raises Price Target to $ 94

TESARO Inc (TSRO) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 94 from a previous price target of $67 . Mizuho advised their investors in a research report released on Jul 5, 2016.

Many Wall Street Analysts have commented on TESARO Inc. TESARO Inc was Downgraded by Jefferies to ” Hold” on Jun 30, 2016. Company shares were Reiterated by FBR Capital on Jun 29, 2016 to “Outperform”, Firm has raised the Price Target to $ 93 from a previous price target of $65 .TESARO Inc was Initiated by Credit Suisse to “Outperform” on May 13, 2016.

On the company’s financial health, TESARO Inc reported $-2.22 EPS for the quarter, missing the analyst consensus estimate by $ -0.54 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-1.68. The company had revenue of $.31 million for the quarter, compared to analysts expectations of $3.54 million. During the same quarter in the previous year, the company posted $-1.30 EPS.

TESARO Inc closed down -2.99 points or -3.56% at $81.06 with 50,79,203 shares getting traded on Friday. Post opening the session at $83.24, the shares hit an intraday low of $80.35 and an intraday high of $83.4 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Jul 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 12,500 shares at $74.02 per share price. According to the SEC, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.


Leave a Reply

TESARO Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TESARO Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.